- GlobeNewswire•5 hours agoTG Therapeutics, Inc. Announces Double & Triple Combination Therapy Data Presentations at the 58th American Society of Hematology Annual Meeting
Combination of TG-1101, TGR-1202 and bendamustine resulted in 71% ORR, including 43% complete response rate, in relapsed or refractory DLBCL. TGR-1202 continues to demonstrate a favorable and differentiated ...
- GlobeNewswire•5 hours ago
NEW YORK, Dec. 06, 2016-- TG Therapeutics, Inc., today announced that the target enrollment of 120 patients in the GENUINE Phase 3 study has been met and enrollment will be closed shortly. The GENUINE ...
- GlobeNewswire•yesterdayTG Therapeutics, Inc. Announces Oral Data Presentation for TGR-1202 in Combination with Ibrutinib in Patients with Relapsed or Refractory CLL or MCL at the 58th American Society of Hematology Annual Meeting
Combination of TGR-1202 plus ibrutinib is well-tolerated with no Grade 3/ 4 transaminitis, pneumonitis, diarrhea, or colitis observed, with patients approaching two years on therapy. 88% ORR in CLL patients, ...
TGTX : Summary for TG Therapeutics, Inc. - Yahoo Finance
TG Therapeutics, Inc. (TGTX)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
|Bid||5.45 x 4300|
|Ask||5.50 x 2400|
|Day's Range||5.43 - 5.68|
|52 Week Range||4.90 - 13.67|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-3.70|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|